三例重症新型冠状病毒肺炎患者右美托咪定相关高热
本文为病例报告,描述2020年初春COVID-19大流行期间在临时ICU收治的三例重症患者(60岁女性、43岁女性、46岁男性)。三例均在右美托咪定剂量增至>1.5 µg/kg/hr后出现定义为体温>41.1°C的高热,停用右美托咪定后发热消退。作者认为高剂量右美托咪定输注似乎在COVID-19重症患者中以剂量依赖方式与高热相关,推测其作为中枢性α2激动剂可能干扰神经递质表达和代谢而改变下丘脑体温调节,在炎症高反应状态下增加高热风险,但确切机制尚不明确。
要点
- 三例重症COVID-19患者均在右美托咪定剂量增至>1.5 µg/kg/hr后出现体温>41.1°C的高热,停用右美托咪定后发热消退。
- 作者认为高剂量右美托咪定输注似乎以剂量依赖方式与COVID-19重症患者的高热相关。
- 作者推测COVID-19的炎症高反应状态合并高剂量右美托咪定可能通过干扰下丘脑体温调节增加高热风险。
- 对使用高剂量右美托咪定镇静的重症COVID-19患者,出现不明原因高热时应考虑药物相关高热并行停药观察。
适用人群与场景
- 2020年初春COVID-19大流行期间收治于临时ICU的三例重症COVID-19患者:60岁女性、43岁女性、46岁男性。
- 均为接受右美托咪定镇静且剂量增至>1.5 µg/kg/hr的重症患者。
诊断标准与关键阈值
- 高热定义为体温>41.1°C。
- 右美托咪定剂量增至>1.5 µg/kg/hr后出现高热。
处置流程与药物剂量
- 三例患者在右美托咪定剂量增至>1.5 µg/kg/hr后出现体温>41.1°C的高热。
- 停用右美托咪定后发热消退。
红旗征与不能漏的情况
- 使用高剂量右美托咪定(>1.5 µg/kg/hr)镇静的重症COVID-19患者出现体温>41.1°C的高热,需考虑右美托咪定相关高热并停药观察。
研究设计与关键结果
- 病例报告:三例重症COVID-19患者(60岁女性、43岁女性、46岁男性)在右美托咪定剂量增至>1.5 µg/kg/hr后出现体温>41.1°C的高热,停用右美托咪定后发热消退。
- 作者认为高剂量右美托咪定输注似乎在COVID-19重症患者中以剂量依赖方式与高热相关,确切机制尚不明确。
证据类型、等级与局限
- 证据类型:病例报告(三例)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对使用右美托咪定镇静且剂量增至>1.5 µg/kg/hr的重症COVID-19患者,出现体温>41.1°C高热时应考虑右美托咪定相关高热,停药后观察发热是否消退。
- 作者认为高剂量右美托咪定在炎症高反应状态下可能增加高热风险,确切机制尚不明确。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To present three patients with severe coronavirus disease 2019 infection who developed life-threatening hyperpyrexia while being treated with dexmedetomidine for sedation.
DATA SOURCES: Clinical records.
STUDY SELECTION: Case report.
DATA EXTRACTION: Relevant clinical information.
DATA SYNTHESIS: We describe three patients, a 60-year-old female, 43-year-old female, and 46-year-old male, who were hospitalized in surge ICUs during the coronavirus disease 2019 pandemic in the early spring of 2020. All developed hyperpyrexia, defined as a temperature above 41.1°C, following an increase in dexmedetomidine dosing to above 1.5 µg/kg/hr. Fevers resolved following discontinuation of dexmedetomidine.
CONCLUSIONS: While the exact mechanism of hyperpyrexia remains unclear, findings in this study suggest that high doses of dexmedetomidine infusion are associated with hyperpyrexia in a seemingly dose-dependent fashion in critically ill patients with coronavirus disease 2019. Coronavirus disease 2019 infection causes a hyperinflammatory state characterized by pro-inflammatory cytokine dysregulation. Dexmedetomidine, a centrally acting alpha-2 agonist, may alter hypothalamic temperature regulation through disturbances in neurotransmitter expression and metabolism. We postulate that the use of high-dose dexmedetomidine in a hyperinflammatory state may increase the risk of developing hyperpyrexia in this severe disease state.
参考来源
- Czepiel KS, Lucas AT, Whalen MJ, et al. Dexmedetomidine-Associated Hyperpyrexia in Three Critically Ill Patients With Coronavirus Disease 2019. Crit Care Explor. 2020. PMID: 32984835. doi:10.1097/CCE.0000000000000213
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。